Editor: Tabish Qidwai

Drug Repurposing Against SARS-CoV-2

eBook: US $59 Special Offer (PDF + Printed Copy): US $101
Printed Copy: US $71
Library License: US $236
ISBN: 978-981-5123-20-3 (Print)
ISBN: 978-981-5123-19-7 (Online)
Year of Publication: 2023
DOI: 10.2174/97898151231971230101

Introduction

Drug repurposing is a cost-effective method of discovering new treatments for diseases than traditional drug development methods. It involves virtual screening of chemical candidates with the aid of computational methods like molecular docking.

Drug Repurposing against SARS-CoV2 focuses on current trends in drug repurposing against the novel coronavirus strains. The book aims to give readers an overview of drug repurposing against COVID-19 and various techniques involved in the process. The book consolidates available information on the pathophysiology, drug targets, and drug repurposing against COVID-19 into a single, convenient resource.

Key features

- An up-to-date compilation of the evidence that supports the drug repurposing for COVID-19.

- How to use repurposing of available drugs for disease therapy.

- Provides an improved understanding of pathophysiology and SARS-CoV2 viral entry pathways.

- Provides references for further reading

Audience:

Undergraduate and postgraduate students with a medical background, research scholars, and scientists working in the area of infectious diseases.

Foreword

Drug repurposing is a process of identifying new uses of approved or investigated drugs. In the current scenario of deadly contagious coronavirus disease 2019 (COVID-19), where no specific treatment options are available, drug repurposing is considered a very effective drug discovery strategy and could be considered the new avenue for the treatment of COVID-19. The book entitled “Drug Repurposing against SARS-CoV2” offers comprehensive and systematic coverage of repurposed and adjuvant drugs highlighting their therapeutic status in COVID-19 patients while assessing the challenges and ethical issues related to repurposing drugs.

The pathophysiology of SARS-CoV2 replication in COVID-19 and their modulation by repurposing drugs is explained in simple and lucid language and also through enriched illustrations. The wealth of information assembled by the authors will be useful to both Pharmacologists and Clinicians.


Uma Bhandari
Department of Pharmacology
School of Pharmaceutical Education and Research (SPER)
Jamia Hamdard
India